Diclofenac
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Diclofenac: From Arthritis and Actinic Keratosis to Juvenile Idiopathic Arthritis
One-Sentence Summary
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) originally used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and actinic keratosis. The TxGNN model predicts it may be effective for Juvenile Idiopathic Arthritis (JIA), the highest-ranked prediction that has any supporting evidence, with 0 registered clinical trials and 14 publications currently supporting this direction. This is mostly an extension within the NSAID-for-arthritis class.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, actinic keratosis (from the knowledge graph; New Zealand licence texts list no indication) |
| Predicted New Indication | Juvenile idiopathic arthritis (see note below) |
| TxGNN Prediction Score | 99.25% |
| Evidence Level | L3 |
| New Zealand Market Status | Cancelled only (no valid licences) |
| Number of Authorizations | 11 (all cancelled) |
| Recommended Decision | Proceed with Guardrails |
Note: The top-ranked TxGNN predictions (hypotrichosis simplex of the scalp, score 99.69%; acromesomelic dysplasia, Hunter-Thompson type; pseudoachondroplasia; and others) have no trials, no literature and no plausible mechanism, so they are rated L5 / Hold. JIA (rank 9, score 99.25%) is the first prediction with meaningful supporting evidence, so this report focuses on it.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for diclofenac were not available in the data compiled for this report. Known pharmacology data list its targets as COX-1 (PTGS1) and COX-2 (PTGS2), with additional interactions at TRPM3, PPARγ, ASIC3 and the amino acid transporter SLC36A1. Diclofenac is a non-selective COX inhibitor that reduces prostaglandin-mediated inflammation, pain and stiffness.
The same mechanism underlies its established use in rheumatoid arthritis and osteoarthritis. JIA shares the inflammatory synovitis phenotype of these conditions, so the prediction is mechanistically coherent. However, it is largely an extension within the NSAID-for-arthritis class rather than a true repurposing to a new mechanism.
By contrast, the other high-scoring predictions (genetic skeletal dysplasias, hereditary hair disorders, WHIM syndrome, alopecia areata) lack any plausible link to COX inhibition and appear to be driven by network proximity in the model.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Most relevant publications on JIA (diclofenac-specific studies first; study types are as inferred from titles and abstracts):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3052965 | 1988 | Single-blind crossover study | Clin Exp Rheumatol | Naproxen vs diclofenac vs tolmetin in 28 children with seronegative juvenile chronic arthritis over 12 weeks |
| 6361986 | 1983 | Clinical study (uncontrolled) | Scand J Rheumatol | Diclofenac sodium in juvenile rheumatoid arthritis, including pharmacokinetics in children aged 2-7 |
| 2235663 | 1990 | Open non-comparative study | Pediatr Med Chir | 26 patients aged 2-16 with polyarticular juvenile chronic arthritis treated with diclofenac sodium |
| 10756785 | 1997 | Comparative study | Rev Med Chir Soc Med Nat Iasi | 100 children with juvenile chronic arthritis: diclofenac vs two other agents (including aspirin) |
| 723822 | 1978 | Clinical report | Minerva Pediatr | Sodium diclofenac in infantile rheumatoid arthritis (no abstract available) |
| 8422565 | 1993 | Review | Br J Rheumatol | Diclofenac, ibuprofen, tolmetin and naproxen are comparable in efficacy and tolerance for joint symptoms in children |
| 1884567 | 1991 | Review | Clin Pharmacokinet | Pharmacokinetics of drugs used in juvenile arthritis, including NSAIDs |
| 11735667 | 2001 | Review | Paediatr Drugs | Risks and benefits of NSAIDs in children compared with paracetamol |
| 17474954 | 2007 | Survey | Paediatr Anaesth | Notes diclofenac is licensed in the UK/Ireland for JRA in children over 1 year; infant PK/PD data lacking |
| 21175420 | 2010 | Review | Crit Rev Ther Drug Carrier Syst | NSAID microencapsulation for arthritis (indirect) |
The literature is old and consists mainly of small, uncontrolled or open-label studies, plus reviews. No modern randomized controlled trial was provided.
New Zealand Market Information
All 11 licences are cancelled; no product is currently valid. The approved indication text was not available for any of them.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 747742 | Voltaren | Suppository 50 mg | Cancelled |
| 269905 | Voltaren D | Dispersible tablet 50 mg | Cancelled |
| 2355981 | Diclofenac Sandoz | Enteric-coated tablet 25 mg | Cancelled |
| 2694352 | Diclofenac Devatis | Eye drops 0.1%, single dose | Cancelled |
| 2356007 | Diclofenac Sandoz | Enteric-coated tablet 50 mg | Cancelled |
Other cancelled licences cover Voltaren injection (25 mg/mL), Voltaren SR 75 mg, and Voltaren suppositories (12.5, 25, 100 mg).
Safety Considerations
- Contraindications / conditions of concern (from the knowledge graph, not label text): hypertension, liver failure and liver disease, drug-induced liver injury, congestive heart failure, heart disease and cardiovascular disease, myocardial infarction, stroke and cerebrovascular disorders, active peptic ulcer disease, inflammatory bowel disease, asthma, diabetes mellitus, blood coagulation disorders, anaemia, hemoglobinopathy, gallbladder disease, substance abuse/dependence and keratitis.
- Drug Interactions: The data compiled for this report list pharmacological targets (COX-1, COX-2, PPARγ, TRPM3, ASIC3, SLC36A1) rather than specific interacting drugs. A formal drug-drug interaction review is still needed.
Please refer to the package insert for authoritative warnings, as label data were not available.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Diclofenac's COX-inhibitory mechanism is consistent with use in JIA, and several small, older clinical studies and reviews support it. However, there are no registered trials, the evidence is dated and low-grade (L3), and there is no valid New Zealand licence. The other top-ranked predictions are model-only (L5) and should be held.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism-of-action data from DrugBank
- Modern, controlled paediatric efficacy and safety data, including dosing in children
- Review of whether a diclofenac product can be re-licensed or supplied in New Zealand, and of cardiovascular, gastrointestinal, hepatic and renal safety in children
- Comparison against current JIA standard of care (e.g. other NSAIDs and disease-modifying agents)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.